上海君澜律师事务所 关于 北京佰仁医疗科技股份有限公司 2020 年限制性股票激励计划 归属、作废及授予价格调整相关事项 之 法律意见书 二〇二五年六月 上海君澜律师事务所 法律意见书 上海君澜律师事务所 关于北京佰仁医疗科技股份有限公司 2020 年限制性股票激励计划 归属、作废及授予价格调整相关事项之 法律意见书 致：北京佰仁医疗科技股份有限公司 上海君澜律师事务所（以下简称"本所"）接受北京佰仁医疗科技股份有 限公司（以下简称"公司"或"佰仁医疗"）的委托，根据《上市公司股权激 励管理办法》（以下简称"《管理办法》"）《上海证券交易所科创板股票上 市规则》（以下简称"《上市规则》"）《科创板上市公司自律监管指南第 4 号—股权激励信息披露》（以下简称"《监管指南》"）《北京佰仁医疗科技 股份有限公司 2020 年限制性股票激励计划（修订稿）》（以下简称"《激励计 划（草案修订稿）》"或"本次激励计划"）的规定，就佰仁医疗本次激励计 划首次授予部分第五个归属期及预留授予部分第三个归属期符合归属条件、作 废部分已授予尚未归属的限制性股票及调整授予价格（以下简称"本次归属、 作废及调整"）相关事项出具本法律意 ...

一、监事会会议召开情况 北京佰仁医疗科技股份有限公司（以下简称"公司"）第三届监事会第七次会 议（以下简称"本次会议"）于 2025 年 6 月 13 日在北京市昌平区科技园东区华昌 路 2 号公司会议室以现场与通讯表决相结合的方式召开，会议通知于 2025 年 6 月 6 日以邮件、电话等方式送达至公司全体监事。本次会议由监事会主席王东辉女士召 集并主持，应到监事 3 人，实到监事 3 人。本次会议的召集和召开程序符合《中华 人民共和国公司法》（以下简称"《公司法》"）和《北京佰仁医疗科技股份有限 公司章程》等相关规定，会议形成的决议合法、有效。 二、监事会会议审议情况 证券代码：688198 证券简称：佰仁医疗 公告编号：2025-020 北京佰仁医疗科技股份有限公司 第三届监事会第七次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 经审议，监事会认为：根据公司 2020 年第二次临时股东大会的授权，董事会对 公司 2020 年限制性股票激励计划（以下简称"本激励计划"）的授予价格进行了调 整，本次调整符 ...

除2名激励对象因离职不符合归属条件外，本次拟归属的65名激励对象符合《公司 法》《证券法》等法律法规、规范性文件及《公司章程》规定的任职资格，符合《管理 办法》《上市规则》《自律监管指南》等法律法规、规范性文件及公司《激励计划（草 案修订稿）》规定的激励对象条件，符合公司本激励计划规定的激励对象范围，其作为 公司本激励计划激励对象的主体资格合法、有效，激励对象获授限制性股票的归属条件 已成就。综上，监事会同意公司本激励计划首次授予部分第五个归属期归属名单。 北京佰仁医疗科技股份有限公司监事会 关于2020年限制性股票激励计划首次授予部分第五个归属期及预留 授予部分第三个归属期归属名单的核查意见 北京佰仁医疗科技股份有限公司（以下简称"公司"）监事会依据《中华人民共和 国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称 "《证券法》"）、《上市公司股权激励管理办法》（以下简称"《管理办法》"）、 《上海证券交易所科创板股票上市规则》（以下简称"《上市规则》"）、《科创板上 市公司自律监管指南第4号——股权激励信息披露》（以下简称"《自律监管指南》"） 等法律法规、规范性文件以及《北京佰仁医 ...

证券代码：688198 证券简称：佰仁医疗 公告编号：2025-019 北京佰仁医疗科技股份有限公司 第三届董事会第十次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 北京佰仁医疗科技股份有限公司（以下简称"公司"）第三届董事会第十次会 议（以下简称"本次会议"）于 2025 年 6 月 13 日在北京市昌平区科技园东区华昌 路 2 号公司会议室以现场与通讯表决相结合的方式召开，会议通知于 2025 年 6 月 6 日以邮件、电话等方式送达至公司全体董事。本次会议由公司董事长金磊先生召集 和主持；应到董事 9 人，实到董事 9 人；公司监事及高级管理人员列席了会议。本 次会议的召集和召开程序、出席会议人员的资格和表决程序均符合《中华人民共和 国公司法》等法律法规及《北京佰仁医疗科技股份有限公司章程》的相关规定，会 议形成的决议合法、有效。 二、董事会会议审议情况 本次会议经与会董事认真审议并表决，一致通过了如下事项： （一）审议通过《关于调整 2020 年限制性股票激励计划授予价格的议 ...

Core Insights - The report highlights a mixed economic outlook with May CPI slightly above consensus expectations while PPI fell short, indicating ongoing inflationary pressures primarily driven by energy prices [3][8][10] - The report identifies a positive trend in high-end equipment manufacturing prices, contrasting with the weakness in energy and raw material prices [3][11] Economic Overview - In May, the CPI experienced a year-on-year decline of 0.1%, primarily due to a 6.1% drop in energy prices, which accounted for approximately 0.47 percentage points of the CPI decline [9][10] - The core CPI rose by 0.6% year-on-year, with service prices increasing by 0.5%, indicating resilience in the service sector despite overall weak domestic demand [8][9] - The PPI saw a year-on-year decrease of 3.3%, with production materials down 4.0% and living materials down 1.4%, reflecting international input factors and domestic price declines [10][11] Market Performance - The report lists key stocks to watch, including SF Holding (顺丰控股), Anji Technology (安集科技), and others, indicating potential investment opportunities in these sectors [2] - The performance of various industry indices shows pharmaceuticals leading with a 2.30% increase, while food and beverage sectors experienced a decline of 0.43% [5] Sector Analysis - The report emphasizes the recovery in certain sectors, particularly high-end manufacturing, which is seeing price increases due to improved supply-demand dynamics [11] - The food and beverage sector's performance is noted as weaker, with a decline in prices, contrasting with the resilience observed in the pharmaceutical sector [5][11]

Core Viewpoints - The market in June is expected to remain in a consolidation phase, with large-cap stocks likely to see a recovery. Domestic demand momentum is anticipated to improve marginally, while April's industrial profits continued to show a recovery trend but experienced a decline in both volume and price. The cost decline was the main driver of profit growth in April. PMI data for May indicates a slight recovery in domestic production demand compared to April. It is expected that growth-stabilizing policies will be implemented alongside resilient external demand, and the trend of weak inventory replenishment is likely to continue in the second quarter. However, global trade policies remain uncertain, compounded by concerns over rising US debt rates, which may pressure market sentiment in the short term. In June, various growth-stabilizing policies are expected to accelerate, maintaining a cautious and oscillating market environment. Key areas to watch for a breakthrough include developments in overseas tariffs and the implementation of domestic growth-stabilizing policies in June [4][10][12]. June Stock Recommendations - The June stock selection by the report includes: - SF Express (Transportation) - Anji Technology (Chemicals) - Bairen Medical (Pharmaceuticals) - Lingnan Holdings (Social Services) - Qingdao Beer (Food and Beverage) - Suochen Technology (Computers) [10][12]. Industry Summaries Transportation Industry: SF Express - SF Express reported a net profit of 2.234 billion yuan in Q1 2025, reflecting a steady growth trend. The company achieved a total express volume of 3.56 billion parcels, a year-on-year increase of 19.7%, with revenue reaching 69.85 billion yuan, up 6.9% year-on-year. The profit growth was primarily driven by the continuous improvement of the product matrix and enhanced service competitiveness. The company also focused on cost control through operational model reforms and network optimization, achieving a gross profit margin of 13.3%, an increase of 0.1 percentage points year-on-year [12][13]. Chemical Industry: Anji Technology - Anji Technology experienced rapid growth in revenue and net profit in 2024 and Q1 2025, driven by increased market coverage and new product introductions. The gross profit margin for 2024 was 58.45%, with a net profit margin of 29.08%. In Q1 2025, the gross profit margin was 55.70%, and the net profit margin was 30.96%. The company is seeing a steady increase in its global market share for polishing liquids, with a projected market size growth for semiconductor CMP polishing materials [14][15]. Pharmaceutical Industry: Bairen Medical - Bairen Medical reported rapid growth in revenue and profit in 2024, with significant increases in its three main business segments. The heart valve replacement and repair segment saw a year-on-year growth of 64.28%. The company is expected to maintain high growth rates in 2025, driven by the approval of its first interventional valve product, which offers significant advantages in terms of operation and safety [17][18]. Social Services Industry: Lingnan Holdings - Lingnan Holdings achieved a revenue of 4.309 billion yuan in 2024, a year-on-year increase of 25.43%, and a net profit of 150 million yuan, up 116.08%. The company’s travel agency operations and hotel management segments are expected to continue growing, particularly with the recovery of inbound tourism and the expansion of hotel management projects [20][21]. Food and Beverage Industry: Qingdao Beer - Qingdao Beer faced pressure on volume and price in Q3 2024, with a year-on-year decline in sales volume of 7.0%. However, the company benefited from a decrease in raw material costs, leading to an improvement in gross profit margins. Future growth is anticipated as restaurant demand recovers, supported by the company's strong brand and distribution network [23][24]. Computer Industry: Suochen Technology - Suochen Technology reported a revenue of 39 million yuan in Q1 2025, a year-on-year increase of 21.73%. The company is focusing on enhancing its CAE software capabilities and exploring AI applications in various fields. The engineering simulation software segment has shown significant growth, contributing to an overall increase in the company's gross profit margin [25][26][27].

Strategy Overview - The market in June is expected to remain in a state of waiting for a breakthrough, with large-cap stocks likely to see a recovery. Domestic demand momentum is anticipated to improve marginally, although April's industrial profits showed a decline in both volume and price, with cost reductions being the main driver for profit growth. The PMI for May indicates a slight recovery in domestic production demand compared to April. It is expected that growth-stabilizing policies will be implemented alongside resilient external demand, continuing the trend of weak inventory replenishment in the second quarter. However, global trade policies remain uncertain, compounded by concerns over rising US debt rates, which may pressure market sentiment in the short term. In June, various growth-stabilizing policies are expected to accelerate, maintaining a volatile consolidation pattern in the market. Key areas to monitor for a breakthrough include overseas tariff developments and the implementation of domestic growth-stabilizing policies in June. [5][7] June Stock Recommendations - The June stock selection by Zhongyin Securities includes: - SF Express (Transportation) - Anji Technology (Chemicals) - Bairen Medical (Healthcare) - Lingnan Holdings (Social Services) - Qingdao Beer (Food and Beverage) - Suochen Technology (Computers) [14][16] Performance Review of May Stock Selection - The stock selection for May outperformed the market, with notable performances from Jiemian Express-W and Yiwei Lithium Energy, both achieving over 10% monthly returns. The absolute return of the May stock selection was 3.87%, outperforming the market benchmark (CSI 300) by 2.02 percentage points. Three stocks achieved excess returns of over 5% compared to the CSI 300. [9] Company-Specific Insights SF Express (Transportation) - In Q1 2025, SF Express reported a net profit of 2.234 billion yuan, reflecting a stable growth trend. The company achieved a total express volume of 3.56 billion parcels, a year-on-year increase of 19.7%, with revenue reaching 69.85 billion yuan, up 6.9% year-on-year. The net profit increased by 16.87% year-on-year, driven by continuous improvement in product matrix and service competitiveness. The gross profit margin was 13.3%, slightly up by 0.1 percentage points. [16][17] Anji Technology (Chemicals) - Anji Technology is expected to see rapid growth in revenue and net profit in 2024, driven by increased market coverage and new product introductions. The gross margin for 2024 is projected at 58.45%, up 2.64 percentage points year-on-year. The company’s polishing liquid revenue reached 1.545 billion yuan in 2024, a year-on-year increase of 43.73%. The global semiconductor CMP polishing materials market is expected to grow from 3.42 billion USD in 2024 to 3.62 billion USD in 2025. [19][20] Bairen Medical (Healthcare) - Bairen Medical reported rapid growth in Q4 2024 and Q1 2025, with significant increases in revenue across all three major business segments. The heart valve replacement and repair segment saw a year-on-year growth of 64.28%. The approval of the TAVR product in August 2024 is expected to drive further growth in 2025. [24][25] Lingnan Holdings (Social Services) - Lingnan Holdings achieved a revenue of 4.309 billion yuan in 2024, a year-on-year increase of 25.43%, with a net profit of 150 million yuan, up 116.08%. The travel agency and hotel management segments are expected to continue growing, particularly with the recovery of inbound tourism. [29][30] Qingdao Beer (Food and Beverage) - Qingdao Beer faced challenges in 2024 with a volume decline of 7.0% and a slight price increase of 0.5%. The company’s gross margin improved due to lower raw material costs, but net profit margin slightly decreased. Future growth is anticipated as restaurant demand recovers. [34][35] Suochen Technology (Computers) - Suochen Technology reported a revenue of 39 million yuan in Q1 2025, a year-on-year increase of 21.73%. The company is focusing on enhancing its CAE software capabilities and exploring AI applications in various fields. [38][39][40]

截至2025年5月23日收盘，佰仁医疗（688198）报收于106.79元，较上周的109.54元下跌2.51%。本周， 佰仁医疗5月20日盘中最高价报110.96元。5月23日盘中最低价报106.47元。佰仁医疗当前最新总市值 146.72亿元，在医疗器械板块市值排名14/126，在两市A股市值排名1036/5148。 本周关注点 公司公告汇总 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 公司公告汇总：佰仁医疗2024年年度权益分派实施，每股现金红利0.80元（含税） 公司公告汇总：佰仁医疗消化外科生物补片注册申请获得国家药品监督管理局受理 佰仁医疗关于自愿披露消化外科生物补片注册申请获得受理的公告，公司在研产品消化外科生物补片注 册申请获国家药品监督管理局正式受理，受理号为CQZ2500902。该产品是国内首个采用牛心包组织作 为原材料的软组织修复产品，有助于减少消化外科胃肠手术常见并发症，促进吻合口愈合。该产品临床 试验结果显示明显优效于对照组，但能否通过注册审批取得注册证具有一定的不确定性。 佰仁医疗2024年年度权益分 ...

证券代码：688198 证券简称：佰仁医疗 公告编号：2025-018 吻合口切缘出血、渗血和胃液、肠液渗漏是消化外科胃肠手术中最常见的术中 与术后并发症。近年来, 消化外科的各类手术几乎均采用切割吻合器实施的微创手术, 由于通过腔镜显露的原因，其术中处理出血或渗血，往往会让手术时间延长，患者 损伤大且并发症多。吻合口出血一般发生在术后24至72小时之内，若发现不及时或 处理不当可危及生命，如果术后发生消化道瘘甚至还不得不再次手术。通过消化外 科生物补片的植用于吻合口加固可避免上述并发症的发生，同时有助于吻合口处损 伤组织的修复，使患者术后恢复有保障。 此前用于吻合口的修补和加固的消化道外科补片分为人工合成高分子材料和生 物材料两类，后者又分为生物衍生材料（以牛肌腱或猪小肠粘膜下层加工而成)和生 物组织材料(经化学改性牛心包或猪心包组织）。与高分子材料比，生物组织材料具 有较好的生物相容性和组织特有的粘弹性，吻合钉与补片之间的蜜接有效地防止术 中和术后出血或渗血以及消化液渗漏，不引起局部炎症反应，具有促进吻合口愈合 的作用。 北京佰仁医疗科技股份有限公司 关于自愿披露消化外科生物补片注册申请获得受理的公 告 ...

证券代码：688198 证券简称：佰仁医疗 公告编号：2025-017 北京佰仁医疗科技股份有限公司2024年年度 权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 15 日的2024年年度股东大会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 重要内容提示： ? 是否涉及差异化分红送转：否 ? 每股分配比例 每股现金红利0.80元（含税） ? 相关日期 股权登记日 除权（息）日 现金红利发放日 （2）对于合格境外机构投资者（QFII）股东，公司根据国家税务总局《关于 中国居民企业向 QFII 支付股息、红利、利息代扣代缴企业所得税有关问题的通知》 （国税函200947 号）的有关规定，按照 10%的企业所得税率代扣企业所得税， 扣税后实际派发现金红利为每股人民币 0.72 元。如相关股东认为其取得的股息 ...